Compare CRSR & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSR | IMCR |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2020 | 2016 |
| Metric | CRSR | IMCR |
|---|---|---|
| Price | $8.41 | $30.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $8.50 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 4.0M | 556.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.37 | 30.39 |
| EPS | 0.11 | ★ 0.25 |
| Revenue | ★ $1,472,480,000.00 | $249,428,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | $6.90 | $8.21 |
| P/E Ratio | ★ $80.00 | $122.16 |
| Revenue Growth | 11.86 | ★ 43.05 |
| 52 Week Low | $4.48 | $27.56 |
| 52 Week High | $13.10 | $40.71 |
| Indicator | CRSR | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 46.88 | 61.86 |
| Support Level | $8.18 | $27.66 |
| Resistance Level | $8.44 | $31.56 |
| Average True Range (ATR) | 0.53 | 1.12 |
| MACD | -0.15 | 0.28 |
| Stochastic Oscillator | 22.10 | 73.84 |
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the United States (U.S.), Americas (excluding U.S.) , Europe and the Middle East, and the Asia Pacific, of which maximum revenue is generated from United States (U.S.).
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.